Headlands Technologies LLC Bei Gene, Ltd. Transaction History

Headlands Technologies LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$129.52 - $174.32 $317,453 - $427,258	2,451 Added 761.18%	2,773 $395,000
Q1 2024 May 07, 2024	BUY	$141.8 - $181.47 $45,659 - $58,433	322 New	322 $50,000
Q3 2023 Nov 09, 2023	SELL	$179.87 - $225.13 $16,907 - $21,162	-94 Reduced 42.15%	129 $23,000
Q2 2023 Aug 03, 2023	BUY	$178.3 - $266.78 $39,760 - $59,491	223 New	223 $39,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Headlands Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Headlands Technologies LLC with notifications on news.